328 related articles for article (PubMed ID: 25664866)
1. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
Seife C
JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
[TBL] [Abstract][Full Text] [Related]
2. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
[TBL] [Abstract][Full Text] [Related]
3. The role of data audits in detecting scientific misconduct. Results of the FDA program.
Shapiro MF; Charrow RP
JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
[TBL] [Abstract][Full Text] [Related]
4. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
Garmendia CA; Epnere K; Bhansali N
Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
[TBL] [Abstract][Full Text] [Related]
5. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
7. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
Garmendia CA; Bhansali N; Madhivanan P
Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
Romano CA; Nair S; Delphin ES
Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
[TBL] [Abstract][Full Text] [Related]
9. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
11. Raising suspicions with the Food and Drug Administration: detecting misconduct.
Hamrell MR
Sci Eng Ethics; 2010 Dec; 16(4):697-704. PubMed ID: 20842536
[TBL] [Abstract][Full Text] [Related]
12. Research misconduct found by FDA inspections of clinical trials is rarely reported in journal studies.
Mayor S
BMJ; 2015 Feb; 350():h747. PubMed ID: 25670690
[No Abstract] [Full Text] [Related]
13. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
Bramstedt KA; Kassimatis K
Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
[TBL] [Abstract][Full Text] [Related]
14. ORI findings of scientific misconduct in clinical trials and publicly funded research, 1992-2002.
Reynolds SM
Clin Trials; 2004; 1(6):509-16. PubMed ID: 16279291
[TBL] [Abstract][Full Text] [Related]
15. Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses.
Roest AM; de Jonge P; Williams CD; de Vries YA; Schoevers RA; Turner EH
JAMA Psychiatry; 2015 May; 72(5):500-10. PubMed ID: 25806940
[TBL] [Abstract][Full Text] [Related]
16. Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
Benjamin DK; Smith PB; Murphy MD; Roberts R; Mathis L; Avant D; Califf RM; Li JS
JAMA; 2006 Sep; 296(10):1266-73. PubMed ID: 16968851
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
Morgan-Linnell SK; Stewart DJ; Kurzrock R
Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
[TBL] [Abstract][Full Text] [Related]
18. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.
Shetty YC; Saiyed AA
J Med Ethics; 2015 May; 41(5):398-403. PubMed ID: 24965716
[TBL] [Abstract][Full Text] [Related]
19. [Retractions due to errors and frauds].
Decullier E; Samson G; Huot L
Presse Med; 2012 Sep; 41(9 Pt 1):847-52. PubMed ID: 22841376
[TBL] [Abstract][Full Text] [Related]
20. Reporting research misconduct in the medical literature.
Steinbrook R; Redberg RF
JAMA Intern Med; 2015 Apr; 175(4):492-3. PubMed ID: 25664939
[No Abstract] [Full Text] [Related]
[Next] [New Search]
